Sign inJoin waitlistJoin the waitlist

Laurence Belkoff

Program Director · Main Line Health System

Credentials: · · ·

History

Main Line Health System
Present

Urology
Albert Einstein Medical Center
1996–2001
DOH/Bi-County Hospital
1991–1996
Detroit Osteopathic Hospital
1988–1991
Botsford Hospital
1987–1988
DO, Kansas City University, College of Medicine and Biosciences, Kansas City, MO
Kansas City University
1983–1987

Research

Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus
Mayo Clinic Proceedings · 2012 · 60 citations
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High-…
European Urology · 2024 · 54 citations
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate…
Clinical Cancer Research · 2013 · 51 citations

NS
Neal Shore
14 papers
Adam Reese
9 papers
Daniel Edwards
9 papers · 9 as a resident
Jay Raman
9 papers
John Danella
9 papers
Robert Uzzo
9 papers
SG
Serge Ginzburg
9 papers
Bruce Jacobs
8 papers
Thomas Guzzo
8 papers
Marc Smaldone
7 papers
Andres Correa
6 papers
Edouard Trabulsi
6 papers

Clinical trials

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
Principal investigator · Unknown · Phase 3
MidLantic Urology
2023–2024
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Site PI · Recruiting
Axonics, Inc.
2024–2028
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Site PI · Recruiting · Phase 2
CG Oncology, Inc.
2024–2027
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Site PI · Unknown
Arquer Diagnostics Ltd
2021–2023